News zum Sektor Gesundheit aus Norwegen

 

The company's first acquisition will more than double Spherex's workforce, expand the brand into cultivation and strengthen control over its supply chainDENVER--(BUSINESS WIRE)--#Cannabis--Spherex, Colorado's leading cannabis brand, today announced an agreement to acquire two cultivation facilities from The Cannabist Company (TCC) and its affiliates, The Green Solution (TGS) and Rocky Mountain Tillage (RMT), as part of TCC's ongoing business restructuring. The transaction represents Spherex's first acquisition and a significant expansion of the company's operations. The expansion includes a Denver-area indoor cultivation facility and an outdoor cultivation operation in Trinidad, Colorado. Approximately 60 employees across the facilities are expected to join Spherex, growing the company from its current workforce to nearly 100 employees. “This is a growth move for Spherex, but it's also the result of how deliberately we've built this business over the past 11 years,” said Dan Gardenswartz, Pres...

Dollar General, Bristol-Myers Squibb and Equinor ASA have been highlighted in this Screen of The Week article....

Dollar General, Bristol-Myers and Equinor stand out after broker rating upgrades, backed by projected earnings growth and resilient U.S. equity markets....

Oslo, 2 October 2026: Reference is made to the stock exchange announcement published by Oncoinvent ASA (the “Company”) on 22 September 2026 regarding completion of a private placement and retail offering of in total 1,650,000 new shares at a subscription price of NOK 90 per share (the “Private Placement”), and the mandatory notification of trade and shareholding disclosure published on 23 September 2026 regarding the allocation of new shares to, and temporary share lending by, Linc AB. In connection with the Private Placement, Linc AB temporarily lent 555,362 existing and unencumbered...

(Tromsø, 01 October 2026) ArcticZymes Technologies ASA (OSE:AZT) will present at the Swiss Nordic Bio 2026 Conference, Zürich taking place today, 01 October 2026. Speaker will be CEO, Michael Akoh Please find the presentation enclosed For further information: Børge Sørvoll CFO +47 952 90 187 ir@arcticzymes.com...

Helsinki, Finland, 30 September 2026: Charles MacBain, a primary insider of Nordhealth AS (the "Company"), has purchased class A shares in the Company. Furthermore, MacBain has assigned derivatives to his close associates, linked to shares in the Company. The derivatives are linked 1:1 with the said shares. Please refer to the attached notification of trading for further details. For further information, please contact: Charles MacBain, CEO, charles.macbain@nordhealth.com Alexander Cram, CFO, alexander.cram@nordhealth.com This information is subject to disclosure requirements...

Oslo, 30 September 2026: Reference is made to the stock exchange announcement published by Oncoinvent ASA (the “Company”) on 22 September 2026 regarding completion of a private placement and retail offering of in total 1,650,000 new shares at a subscription price of NOK 90 per share (the “Private Placement”), and the mandatory notification of trade and shareholding disclosure published on 23 September 2026 regarding the allocation of new shares to, and temporary share lending by, Hadean Capital I AS, HVentures Capital I AB and Hadean Growth Fund I AS. In connection with the Private...

Oslo, 30 September 2026 - Observe Medical ASA (the "Company" or "Observe Medical") today announces a repeat customer order for UnoMeter Safeti MAX, following a comprehensive customer evaluation and successful testing of the product and its unique, patented technology. The repeat order follows the customer's thorough evaluation of UnoMeter Safeti MAX in clinical use, including its innovative product features and the potential clinical and health-economic benefits of the solution. Following the successful evaluation, the customer has chosen to place a new order, providing an important...

Reference is made to the stock exchange announcement made by Oncoinvent ASA (the "Company") on 22 September 2026 regarding the successful private placement of 1,531,000 new shares (the "Private Placement"), divided on a first tranche of 990,689 shares ("Tranche 1") and a second tranche of 540,311 shares ("Tranche 2"), and the allocation of 119,000 new shares in a retail offering carried out via Nordnet (the "Retail Offering"). The share capital increase pertaining to the issuance of the in total 1,650,000 new shares in the Private Placement and Retail Offering (the "New Shares") has now...

Oslo, Norway – 30 September 2026 – Oncoinvent, a clinical-stage radiopharmaceutical company developing Radspherin[®], a receptor-independent alpha-emitting therapy to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces that three abstracts from its Radspherin[®] program have been accepted for presentation at the European Association of Nuclear Medicine (EANM) Annual Congress 2026 (https://eanm26.eanm.org/) in Vienna, Austria (17-21 October) and the European Society for Medical Oncology (ESMO) Congress 2026 (https://www.esmo.org/meeting-...

Helsinki, Finland, 25 September 2026: Karan Wallia, a primary insider of Nordhealth AS (the "Company"), has purchased class A shares in the Company. Please refer to the attached notification of trading for further details. For further information, please contact: Charles MacBain, CEO, charles.macbain@nordhealth.com Alexander Cram, CFO, alexander.cram@nordhealth.com This information is subject to disclosure requirements set out in the Market Abuse Regulation EU 596/2014 Article 19 and the Norwegian Securities Trading Act Section 5-12....

Reference is made to the retail offering (the "Retail Offering") announced by Oncoinvent ASA on 22 September 2026. Please see the attached PDMR-form related to allocation of shares to a primary insider in the Retail Offering. PDMR attachment Soug.pdf (https://mb.cision.com/Public/15728/4399680/b36f04eb98abb5b4.pdf) This information is published in accordance with article 19 of the EU Market Abuse Regulation (MAR)....

Reference is made to the stock exchange announcement by Oncoinvent ASA (the "Company") on 22 September 2026 regarding the successful completion of a private placement and retail offering of 1,650,000 new shares at NOK 90.00 per share, and to the share lending agreement entered into between the Company, ABG Sundal Collier ASA and DNB Carnegie, a part of DNB Bank ASA (the "Managers"), Hadean and Linc AB (the "Share Lending Agreement"). On 22 September 2026, Linc AB agreed to lend 555,362 shares in the Company to the Managers under the Share Lending Agreement, to facilitate delivery-versus-...

The shares in Oncoinvent ASA will from today, 23 September 2026, be traded exclusive of the right to participate in the contemplated subsequent offering announced on 22 September 2026. This information is published in accordance with the requirements of the Continuing Obligations for Euronext Oslo Børs....

Oslo, 23 September 2026: Reference is made to the stock exchange announcement published by Oncoinvent ASA (the "Company") on 22 September 2026 regarding completion of a private placement of 1,650,000 new shares at a subscription price of NOK 90 per share (the "Subscription Price") (the "Private Placement"). Prior to the share lending described below, Hadean Capital I AS, HVentures Capital I AB and Hadean Growth Fund I AS held an aggregate of 554,327 shares in the Company, equal to approximately 12.38% of the shares and votes in the Company. Hadean Capital I AS held, prior to the...

Reference is made to the stock exchange announcement made by Oncoinvent ASA (the "Company") on 22 September 2026 regarding the allocation of 1,531,000 new shares in the Company in a private placement (the "Private Placement") and 119,000 new shares in a retail offering, and a potential subsequent repair offering of up to 200,000 new shares at the same subscription price as in the Private Placement and the retail offering (the "Subsequent Offering"). The Subsequent Offering will, subject to applicable securities law, be directed towards existing shareholders in the Company as of 22 September...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, SOUTH AFRICA, NEW ZEALAND, JAPAN OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Reference is made to the stock exchange announcement made by Oncoinvent ASA (the "Company") on 22 September 2026 regarding the launch of a private placement of new shares in the Company (the "Offer Shares") (the "Private Placement") at a fixed price per share of NOK 90.00...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, SOUTH AFRICA, NEW ZEALAND, JAPAN OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL Oncoinvent ASA ("Company") has retained ABG Sundal Collier ASA and DNB Carnegie, a part of DNB Bank ASA (the "Managers") to advise on and effect a contemplated private placement of new shares in the Company (the "Offer Shares"), raising gross proceeds of up to NOK...

Oslo, 22 September 2026 - Observe Medical ASA (the "Company" or "Observe Medical") today announces the launch of its new website, designed to create a direct, responsive dialogue with healthcare decision-makers about UnoMeter™ Safeti™ Max, an innovative solution with the potential to deliver clear clinical and health-economic advantages. The new digital platform provides healthcare leaders, decision-makers, clinicians and other stakeholders with accessible information about UnoMeter™ Safeti™ Max and the rest of the Company's portfolio, its clinical evidence and its contribution to more...

OSLO, NORWAY – 22 September 2026: Genetic Analysis AS (“GA” or “the Company”) announces today that Canadian patent application 3039144 has been allowed for grant.  The patent protects an in vitro diagnostic method designed to identify patients with Irritable Bowel Syndrome (IBS) who are more likely to respond to treatment with Faecal Microbiota Transplantation (FMT), strengthening GA's intellectual property position within microbiome-based companion diagnostics. IBS is a common gastrointestinal disorder affecting an estimated 5-10% of the global population. Around 70% of IBS patients are...